J B Chemicals & Pharmaceuticals Ltd's Stock Sees Dip, Rated 'Buy' by MarketsMOJO
J B Chemicals & Pharmaceuticals Ltd's stock saw a dip of -3.84% on October 3rd, closing at Rs 1770.05. However, this does not reflect the company's overall performance, as it has been consistently performing well. According to MarketsMojo, the stock is currently rated as 'Buy', indicating a positive future outlook.
J B Chemicals & Pharmaceuticals Ltd, a leading player in the pharmaceuticals and drugs industry, saw a dip in its stock price on October 3rd, 2024. The stock closed at Rs 1770.05, down by -3.84% from the previous day's closing price. However, this dip in stock price does not reflect the company's overall performance, as it has been consistently performing well in the market.
According to MarketsMOJO, a leading stock analysis platform, J B Chemicals & Pharmaceuticals Ltd's stock is currently rated as 'Buy'. This is a positive indication for investors, as the company's stock is expected to perform well in the future.
In terms of price performance, J B Chemicals & Pharmaceuticals Ltd has underperformed the sector by -3.72% on October 3rd. However, this is a short-term trend and does not reflect the company's long-term potential.
It is worth noting that the stock has been on a consecutive fall for the last 2 days, with a -5.7% decline in returns during this period. This could be a result of market fluctuations and does not reflect the company's financial stability.
On October 3rd, the stock touched an intraday low of Rs 1762.2, showing a -3.99% decrease from its opening price. However, the stock's moving averages are still higher than the 200-day moving average, indicating a positive trend in the long run.
In comparison to the overall market performance, J B Chemicals & Pharmaceuticals Ltd's stock has underperformed the Sensex by -1.53% on October 3rd. However, in the past month, the company's stock has outperformed the Sensex by 0.51%, showing its resilience in a volatile market.
Overall, J B Chemicals & Pharmaceuticals Ltd remains a strong player in the pharmaceuticals and drugs industry, with a positive outlook for its stock performance. Investors can consider this as an opportunity to buy the stock at a lower price and potentially reap long-term benefits.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
